Iterum Therapeutics PLC
NASDAQ:ITRM
Iterum Therapeutics PLC
NASDAQ:ITRM
Price:
1.57 USD
-2.48%
Market Closed
Updated:
May 10, 2024
Iterum Therapeutics PLC
Pre-Tax Income
|
Iterum Therapeutics PLC
Pre-Tax Income Peer Comparison
Comparables:
PRGO
JAZZ
AVDL
G
GHRS
COPN
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Pre-Tax Income
-$37.8m
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Pre-Tax Income
-$8.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Pre-Tax Income
$241.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
4%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Pre-Tax Income
-$160.8m
|
CAGR 3-Years
-216%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-11%
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Pre-Tax Income
-$35.6m
|
CAGR 3-Years
-329%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Pre-Tax Income
€7.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-20%
|
See Also
What is Iterum Therapeutics PLC's Pre-Tax Income?
Pre-Tax Income
-37.8m
USD
-37.8m
USD
Based on the financial report for Dec 31, 2023, Iterum Therapeutics PLC's Pre-Tax Income amounts to -37.8m USD.
What is Iterum Therapeutics PLC's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
13%
13%
Over the last year, the Pre-Tax Income growth was 14%. The average annual Pre-Tax Income growth rates for Iterum Therapeutics PLC have been 10% over the past three years , 13% over the past five years .
You don't have any saved screeners yet
